|
|
|
|
|
|
Retrospective Longitudinal Study of the Health Economics of Preventing Post-Surgical Adhesions: Using actual claims data from a private insurer,
Health Advances quantified the incidence and costs related to the diagnosis and treatment of an important post-surgical complication. From this analysis, the
value to payers, hospitals and physicians was quantified. Finally, a demand curve was developed looking at the value by type of precipitating surgery and patient
demographics versus the number of individuals in that segment. This facilitated the identification of the revenue-maximizing price point for this product,
from a purely cost-effectiveness perspective. At the request of the client, Health Advances drafted a manuscript of this groundbreaking work for publication.
Currently the client is seeking a clinician to serve as a co-author to the study.
Assessment of the Clinical Need and Top-level Economics of Infection Prevention for Dialysis Catheters and other Dialysis Devices and Equipment:
As part of a large project identifying and evaluating clinical need and market potential for antimicrobial coatings on a broad range of medical devices, Health Advances
conducted primary and secondary research on devices used for dialysis patients, including catheters and dialyzing equipment. Analysis included quantifying the incidence
of infection in dialysis patients and gaining an understanding of the source and cause of infection to assess the feasibility of applying a proprietary antimicrobial
coating technology to some or all of the devices used on dialysis patients.
Documentation of the Clinical Pathways and Analysis of a Physician's Research Database to Develop a System Economics Basis for FDA Approval and
Market Pricing: Health Advances identified and analyzed a large research database developed by a leading orthopedic surgeon to assess the frequency of different
corrective procedures for damaged knee cartilage and their outcomes. Quantitative and qualitative measures of outcomes were captured, including timing to subsequent treatments.
This information was combined with primary interviews with orthopedic surgeons to document the current clinical pathways by patient segment. The Health Advances team also
quantified the economics of a novel therapeutic procedure, assuming a range of success rates as experienced in clinical trials. This work was included in the BLA filed with
the FDA and, subsequently, approval was granted.
Quantification of the Health Economics for Various Constituencies: By mapping out the current diagnostic pathway for detection of palpable versus non-palpable
breast cancer, and overlaying the reimbursement levels for each node in the pathway with reimbursement to the facility, doctor and/or lab, Health Advances quantified the value
of substituting the novel diagnostic test at each node vs. current protocol. This resulted in identifying the revenue-maximizing point in the diagnostic work-up at which to
position this device. Health Advances also documented the key decision makers for each type of test and, hence, understood who would be "gainers" versus "losers" from the
clinician's perspective by replacing a current method with this new device. Finally, because assumptions for sensitivity and specificity of the new device were implicit in the
economic calculation, the cost effectiveness model allowed the client to quantify the economic impact of various sensitivity/specificity tradeoffs to optimize revenues.
Subsequently, Health Advances conducted follow-on work to quantify the economics for the device in several major European markets and in Japan.
Study of the European Clinical and Reimbursement Practices: Health Advances researched the clinical practice patterns and reimbursement practices and rates for
eight European countries with respect to home hemodialysis. The study included primary interviews with physicians in each country to understand similarities and differences in
practice patterns for treating dialysis patients and drivers of those practice patterns in each country.
|
|
 |
|
|
|
|
